Compare · AZN vs NATR
AZN vs NATR
Side-by-side comparison of AstraZeneca PLC (AZN) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $563.07B, about 1620.4x NATR ($347.5M).
- Over the past year, AZN is down 3.5% and NATR is up 36.4% - NATR leads by 40.0 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 17 for NATR).
- AZN has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- AstraZeneca PLC
- Nature's Sunshine Products Inc.
- Price
- $181.67-2.33%
- $19.86+0.35%
- Market cap
- $563.07B
- $347.5M
- 1M return
- -0.57%
- -18.86%
- 1Y return
- -3.51%
- +36.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 21
- 17
- Recent ratings
- 25
- 5
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest NATR
- EVP & President, Asia Norman Daniel C sold $200,476 worth of shares (9,713 units at $20.64), decreasing direct ownership by 17% to 47,276 units (SEC Form 4)
- EVP, General Counsel Brower Nathan G sold $262,408 worth of shares (12,015 units at $21.84), decreasing direct ownership by 22% to 43,438 units (SEC Form 4)
- Director Fasching Steven J. was granted 4,500 shares, increasing direct ownership by 41% to 15,369 units (SEC Form 4)
- Director Wissmiller Heidi was granted 4,500 shares, increasing direct ownership by 12% to 41,667 units (SEC Form 4)
- EVP & President, Europe Yates Bryant J was granted 8,753 shares, increasing direct ownership by 11% to 89,414 units (SEC Form 4)
- EVP, Global Supply Chain Fritz Erich A was granted 9,226 shares, increasing direct ownership by 79% to 20,889 units (SEC Form 4)
- Director May Katie was granted 4,500 shares, increasing direct ownership by 46% to 14,266 units (SEC Form 4)
- EVP, General Counsel Brower Nathan G was granted 9,001 shares, increasing direct ownership by 19% to 55,453 units (SEC Form 4)
- Chief Executive Officer Romanzi Kenneth G. was granted 33,753 shares, increasing direct ownership by 31% to 143,999 units (SEC Form 4)
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 6,107 shares, increasing direct ownership by 14% to 48,392 units (SEC Form 4)